mogamulizumab

Home
Ligands
mogamulizumab

GtoPdb Ligand ID: 6477

Synonyms: KW-0761 | mogamulizumab-kpkc | Poteligeo®

mogamulizumab is an approved drug (PMDA (Japan, 2012), EMA & FDA (2018))

Comment: Mogamulizumab (KW-0761) is a CCR4-targeting mAb with enhanced antibody-dependent cellular cytotoxicity (ADCC) function. It is the only GPCR-targeting mAb on the market (in July 2017).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Immunopharmacology Comments
Mogamulizumab is a CCR4-targeted immuno-oncology drug. It is intended to deplete CCR4-expressing T_reg cells in the tumour microenvironment so as to release of T_eff cells from T_reg-mediated suppression, and facilitate tumour cell killing. However, it also targets extratumoural T_reg cells that serve other vital immune cell functions, and can induce serious side effects such as dermatologic toxicity and autoimmune issues [2-3].

Immunopharmacology Comments

Mogamulizumab is a CCR4-targeted immuno-oncology drug. It is intended to deplete CCR4-expressing T_reg cells in the tumour microenvironment so as to release of T_eff cells from T_reg-mediated suppression, and facilitate tumour cell killing. However, it also targets extratumoural T_reg cells that serve other vital immune cell functions, and can induce serious side effects such as dermatologic toxicity and autoimmune issues [2-3].

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Adult T-cell leukemia	Disease Ontology: DOID:0050523	An anti-CCR4 monoclonal antibody approved for relapsed or refractory adult T-cell leukemia/lymphoma.
Cutaneous T cell lymphoma	Disease Ontology: DOID:0060061	Approved drug for two subtypes of cutaneous lymphoma: mycosis fungoides or Sézary syndrome- FDA 2018.